Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AN
Alto Neuroscience Inc.
ANRO
Mkt Cap
$862.5M
Volume
520.89K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AN
ANRO
AN
Alto Neuroscience Inc.
ANRO
News
·
Here's Why You Should Add ANRO Stock to Your Portfolio Now
Mkt Cap
$861.0M
Volume
520.88K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Insider
Filings
Here's Why You Should Add ANRO Stock to Your Portfolio Now
Alto Neuroscience (ANRO), a clinical-stage biopharmaceutical company, is advancing its precision psychiatry pipeline with three key candidates. ALTO-207 for treatment-resistant depression showed encouraging phase IIa results, with phase IIb results expected in H2 2027. ALTO-300 and ALTO-100 are in phase IIb studies with top-line results expected in H1 2027 and mid-2027 respectively. ALTO-101 for schizophrenia-related cognitive impairment failed its primary endpoint but showed some secondary signals. Year-to-date, ANRO shares have risen 24.1%, outperforming the biotech industry's 2.9% growth.
Zacks Investment Research · Oct 14, 2026
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
The psychedelic medicine sector is advancing with regulatory momentum, as the first psilocybin compound achieved two positive Phase 3 results in treatment-resistant depression. The DEA increased its 2026 psilocybin production quota by 67%. Five companies—Helus Pharma, Compass Pathways, Relmada Therapeutics, Alto Neuroscience, and Axsome Therapeutics—are progressing clinical programs targeting depression, anxiety, cognitive impairment, bladder cancer, and Alzheimer's agitation.
Benzinga · Feb 26, 2026
ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Law firm investigating potential claims against Alto Neuroscience after stock price dropped 69.99% following disappointing Phase 2b trial results for ALTO-100 depression treatment.
GlobeNewswire Inc. · Oct 7, 2025
Investors who lost money on Alto Neuroscience, Inc.(ANRO) should contact Levi & Korsinsky about pending Class Action - ANRO
Levi & Korsinsky is notifying investors of a class action lawsuit against Alto Neuroscience regarding alleged securities fraud related to misleading statements about their product pipeline's effectiveness in treating major depressive disorder.
GlobeNewswire Inc. · Sep 19, 2025
ANRO DEADLINE TODAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRO
Rosen Law Firm alerts Alto Neuroscience investors about a securities class action lawsuit alleging false statements about the company's drug ALTO-100 and its effectiveness in treating major depressive disorder.
GlobeNewswire Inc. · Sep 19, 2025
ANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Alto Neuroscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
A class action lawsuit has been filed against Alto Neuroscience alleging misleading statements about their IPO and drug ALTO-100's effectiveness in treating major depressive disorder.
GlobeNewswire Inc. · Sep 18, 2025
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
Faruqi & Faruqi is investigating potential securities claims against Alto Neuroscience after the company's stock dropped 69.99% following disappointing Phase 2b trial results for ALTO-100 in treating Major Depressive Disorder (MDD).
GlobeNewswire Inc. · Sep 18, 2025
ANRO DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRO
Rosen Law Firm alerts Alto Neuroscience investors about a securities class action lawsuit alleging false statements about the company's drug effectiveness and business prospects, with a September 19, 2025 lead plaintiff deadline.
GlobeNewswire Inc. · Sep 16, 2025
ANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Alto Neuroscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
A class action lawsuit has been filed against Alto Neuroscience alleging misleading statements about their IPO and drug ALTO-100's effectiveness in treating major depressive disorder.
GlobeNewswire Inc. · Sep 14, 2025
ANRO DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRO
Rosen Law Firm alerts Alto Neuroscience investors about a September 19, 2025 deadline for a securities class action lawsuit alleging false statements about the company's drug effectiveness and business prospects.
GlobeNewswire Inc. · Sep 12, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AN
ANRO
Alto Neuroscience Inc.
Buy
Sell
Market
Limit
Soon
ANRO
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ANRO yet.
Related Tickers
Earnings